Navigation Links
Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui

BALTIMORE, Feb. 2 /PRNewswire/ -- Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in the United States District Court for the Northern District of Illinois in Chicago.  XenoTech and Sekisui Medical are wholly-owned subsidiaries of Sekisui Chemical.  The complaint alleges that certain processes and methods performed by XenoTech associated with its in vitro drug testing services and its pooled cryopreserved hepatocyte products, including CryoXTreme™, infringes one or more claims of U.S. Patent No. 7,604,929 (the '929 patent).  The complaint also alleges that Sekisui Chemical and Sekisui Medical are inducing infringement of the '929 patent and seeks monetary damages and injunctive relief.  Celsis IVT is represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producing cryopreserved hepatocytes.  In general, this technology combines hepatocytes from multiple donors to create large lots with targeted activity levels, the result of which is a product that speeds up decision making and reduces the time and cost of drug research.  Since 2005, Celsis IVT has used this novel technology to create its unique LiverPool™ products for drug discovery research.  Major pharmaceutical companies around the world have incorporated these LiverPool products into their standard research protocols.  Research conducted with LiverPool has confirmed its outstanding efficacy as a research tool in numerous ADME-Tox assays, including metabolic stability and clearance studies.  Additional LiverPool product information is available online at

"Innovation is the lifeblood of Celsis and the entire life sciences industry.  It must be protected if we are to advance the cause of cost-effective drug discovery," said Jay LeCoque, CEO of Celsis.  "We are disappointed that we are forced to take a litigation path after an unsuccessful attempt to meaningfully discuss our proprietary rights with XenoTech," he added, "Yet, we remain hopeful that the Defendants will cooperate with us to reach a successful resolution."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis International Ltd., is the premier world provider of specialized in vitro products for the study of metabolism, drug-drug interactions and toxicity in drug discovery and development.  Since 1990, pharmaceutical and biotechnology companies have relied on Baltimore-based Celsis IVT for quality in vitro products for lead optimization.  Celsis IVT products deliver faster time to results, enabling more productive and cost-effective research.  Celsis IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's largest inventory) and other ADMET research tools are available worldwide. Visit for more information.

About Celsis International Ltd.

Chicago-based Celsis International Ltd. is a leading global provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries.  Each Celsis division delivers substantial time and cost savings to its customers while ensuring product quality and safety for consumers.  Celsis' extensive client base includes leading pharmaceutical and consumer products companies, including all 25 of the top 25 pharmaceutical companies worldwide. Visit

SOURCE Celsis International Ltd.



SOURCE Celsis International Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
2. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
3. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
4. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
5. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
8. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
9. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
10. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
11. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
Post Your Comments:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):